MannKind Corp
MNKD4.960USD
+0.010+0.20%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.50BCap. mercado
54.47P/E TTM
Más Datos de MannKind Corp Compañía
MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company's technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices. In its endocrine business unit, it commercializes two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its pipeline products include Pediatric Afrezza (insulin human) Inhalation Powder, MNKD-101 and MNKD-201.
Información de la empresa
Código de la empresaMNKD
Nombre de la empresaMannKind Corp
Fecha de salida a bolsaJul 28, 2004
Fundada en1991
Director ejecutivoDr. Michael E. Castagna, Pharm.D.
Número de empleados407
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 28
Dirección1 Casper Street
CiudadDANBURY
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal06810
Teléfono18186615000
Sitio Webhttps://mannkindcorp.com/
Código de la empresaMNKD
Fecha de salida a bolsaJul 28, 2004
Fundada en1991
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.47M
-2.62%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
696.53K
-9.51%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
609.34K
+16.18%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
252.00K
--
Dr. Burkhard Blank, M.D.
Dr. Burkhard Blank, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
194.25K
-28.25%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
176.15K
--
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Ms. Jennifer Grancio
Ms. Jennifer Grancio
Independent Director
Independent Director
110.70K
--
Dr. Sabrina Kay
Dr. Sabrina Kay
Independent Director
Independent Director
107.03K
--
Ms. Lauren M. Sabella
Ms. Lauren M. Sabella
Executive Vice President - Operations
Executive Vice President - Operations
106.41K
-45.01%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.47M
-2.62%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
696.53K
-9.51%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
609.34K
+16.18%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
252.00K
--
Dr. Burkhard Blank, M.D.
Dr. Burkhard Blank, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
194.25K
-28.25%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
176.15K
--
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
Product sales
178.56M
62.54%
Royalties
102.33M
35.84%
Services
4.61M
1.62%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
285.50M
0.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product sales
178.56M
62.54%
Royalties
102.33M
35.84%
Services
4.61M
1.62%
Accionista
Hora de actualización: dom., 23 de feb
Hora de actualización: dom., 23 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
BlackRock Institutional Trust Company, N.A.
6.98%
The Vanguard Group, Inc.
5.26%
State Street Global Advisors (US)
3.27%
Avoro Capital Advisors LLC
2.88%
Nitorum Capital, L.P.
2.88%
Other
78.72%
Estadísticas de accionistas
Accionista
Proporción
BlackRock Institutional Trust Company, N.A.
6.98%
The Vanguard Group, Inc.
5.26%
State Street Global Advisors (US)
3.27%
Avoro Capital Advisors LLC
2.88%
Nitorum Capital, L.P.
2.88%
Other
78.72%
Tipo
Accionista
Proporción
Investment Advisor/Hedge Fund
24.45%
Investment Advisor
16.58%
Hedge Fund
10.78%
Research Firm
3.38%
Individual Investor
1.63%
Pension Fund
0.35%
Bank and Trust
0.33%
Venture Capital
0.02%
Other
42.48%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
464
175.74M
57.84%
+7.73M
2024Q4
470
175.08M
57.68%
+5.91M
2024Q3
459
161.03M
58.24%
+6.62M
2024Q2
442
145.29M
52.88%
-4.76M
2024Q1
433
140.98M
52.03%
-8.31M
2023Q4
422
141.98M
52.59%
-12.51M
2023Q3
418
148.17M
55.00%
-3.06M
2023Q2
412
143.59M
53.56%
-12.28M
2023Q1
412
147.80M
55.93%
-4.58M
2022Q4
408
144.92M
55.01%
+311.67K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
21.21M
6.98%
+360.93K
+1.73%
Dec 31, 2024
The Vanguard Group, Inc.
16.00M
5.26%
+420.33K
+2.70%
Dec 31, 2024
State Street Global Advisors (US)
9.95M
3.27%
+350.64K
+3.65%
Dec 31, 2024
Avoro Capital Advisors LLC
8.75M
2.88%
--
--
Dec 31, 2024
Nitorum Capital, L.P.
8.75M
2.88%
-410.19K
-4.48%
Dec 31, 2024
Geode Capital Management, L.L.C.
6.37M
2.1%
+35.35K
+0.56%
Dec 31, 2024
Two Sigma Investments, LP
6.27M
2.06%
+579.24K
+10.18%
Dec 31, 2024
Arrowstreet Capital, Limited Partnership
4.89M
1.61%
+3.59M
+275.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.48M
1.47%
+49.96K
+1.13%
Dec 31, 2024
D. E. Shaw & Co., L.P.
4.27M
1.41%
+798.47K
+23.01%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: hace 7 horas
Hora de actualización: hace 7 horas
Nombre
Proporción
Invesco Biotechnology & Genome ETF
2.3%
ALPS Medical Breakthroughs ETF
1.18%
VictoryShares Small Cap Free Cash Flow ETF
0.61%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Federated Hermes MDT Small Cap Core ETF
0.42%
First Trust Small Cap Growth AlphaDEX Fund
0.41%
Global X Aging Population ETF
0.32%
iShares Micro-Cap ETF
0.29%
SPDR S&P Biotech ETF
0.28%
First Trust Small Cap Core Alphadex Fund
0.21%
Ver más
Invesco Biotechnology & Genome ETF
Proporción2.3%
ALPS Medical Breakthroughs ETF
Proporción1.18%
VictoryShares Small Cap Free Cash Flow ETF
Proporción0.61%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.44%
Federated Hermes MDT Small Cap Core ETF
Proporción0.42%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.41%
Global X Aging Population ETF
Proporción0.32%
iShares Micro-Cap ETF
Proporción0.29%
SPDR S&P Biotech ETF
Proporción0.28%
First Trust Small Cap Core Alphadex Fund
Proporción0.21%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos